SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.
Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely enables them to hide from immune attack.
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential to address unmet needs in multiple ...
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...
Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...